Navigation Links
AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
Date:6/6/2009

Two-year study presented at the American Diabetes Association's 69th Scientific Sessions shows investigational product comparable to standard insulin therapy in pulmonary function tests

NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin with changes in pulmonary function tests comparable to usual antidiabetic treatment, according to data presented today at the American Diabetes Association's 69th Scientific Sessions. Results from the prospective, multicenter, phase 3 study conducted over a two-year period showed no difference in mean change in forced expiratory volume in one second (FEV(1)) between those treated with AFRESA and those treated with standard insulin therapy.

"Current mealtime insulin therapies, while accepted as an effective means to control glucose levels, have several limitations," said Peter Richardson, Corporate Vice President and Chief Scientific Officer, MannKind Corporation. "Our encouraging findings indicate that AFRESA may be a promising new treatment option with less weight gain and lower risk of hypoglycemia compared with current mealtime insulin therapy."

AFRESA is a novel, ultra rapid acting mealtime insulin therapy with an action profile that mimics meal-related early insulin release. Based on an extensive phase 3 clinical program, a New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA) requesting approval to market AFRESA Inhalation Powder and the AFRESA Inhaler for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia. AFRESA is conveniently administered by oral inhalation.

Diabetes, which affects 23.6 million people in the U.S., or 8 percent of the population, is characterized by the body's inability to properly regulate levels of blood glucose, or blood sugar. Insulin, a hormone
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
2. PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
3. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
4. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
5. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
6. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
9. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
10. TNFerade(TM) Phase III Data Presented at ASCO
11. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...initeMind ,aSaltLakeCitybasedsoftwarecompany,annou...thesoftwareprogramistobeusedinconjunctionwithexist...cedattheCOVDconferencethisOctoberinColorado.Curren...e eyeQ programaddssignificantvaluetohispractice,Se...entstoembedpracticesfromtheofficesettingtothecomfo...
(Date:11/24/2009)...re/--America,spharmaceuticalresearchandbiotechnolo...orpreventHIV/AIDSandrelatedconditions,accordingtoa...ndManufacturersofAmerica(PhRMA).December1marksthe2...paignthatoriginatedatthe1988WorldSummitofMinisters...egreatlyencouragedbythesecriticallyimportantmedici...
(Date:11/24/2009)...HuifengBio-Pharmaceutical,Technology,Inc.(OTCBulle...textractsandpharmaceuticalrawmaterialsforuseinphar...China,todayreportedthatinits,thirdquarter,thecompa...orthequarterendedSept.30,2009were$4,465,770,anincr...terin2008.Netincome,amountedto1,002,005,or$0.05per...
Breaking Medicine Technology:Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3Rigel Announces Presentations at Two Investor Conferences 5773 1Rigel Announces Presentations at Two Investor Conferences 5773 2DigitalPersona to Speak at Dallas SecureWorld Expo 10550 1DigitalPersona to Speak at Dallas SecureWorld Expo 10550 2WuXi PharmaTech Schedules Third Quarter 2009 Earnings Release 60216 1WuXi PharmaTech Schedules Third Quarter 2009 Earnings Release 60216 2
...y transplant recipients off,anti-rejection drugs f...plant surgery,anti-rejection drugs for the organ r...ve serious side effects, including infections, hea..., MD, a researcher at Northwestern,University,s Fe...stern,Memorial Hospital,s department of organ tran...
...nnounces $7,800 Wholesale Price for ...1 AIDS Healthcare,Foundation (AHF) today urged Ti...& Johnson, to reconsider and reduce its steep pric...a non-nucleoside reverse transcriptase,inhibitor, ...on (FDA),approval on Friday after a fast track or ...
Other Medicine Technology:Northwestern Memorial Transplant Program Initiates New Study 2Northwestern Memorial Transplant Program Initiates New Study 3Northwestern Memorial Transplant Program Initiates New Study 4AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine 2AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine 3
(Date:11/25/2009)...aliforniaMakesLittleProgresstoImproveOverallOutcom...re-USNewswire/-- Today,LungCancerAlliance-Califor...er .The2009ReportCardisanassessmentofprogressbeing....LCA-CAisachapterofLungCancerAlliance(LCA),theonly...upportandadvocacyforpeoplelivingwithoratriskforlun...
(Date:11/25/2009)...ES (Nov. 25, 2009) Melvin R. Kaplan, MD, FACP, a ...research institute that became Los Angeles Biomedi...er (LA BioMed), will be honored by the American Co...he care of patients. , At its April 22, 2010 mee...s will present Dr. Kaplan with the Ralph O. Claypo...
(Date:11/25/2009)...n fruit fly study may lead to new drugs for people... (HealthDay News) -- Sphingadienes, natural lipid ...ent in treatments for colon cancer, California res...inary, but the study authors pointed out that they...ction against colon cancer. , In the study, Dr....
(Date:11/25/2009)... Citing support for recent enforceme...s, the National Association of Chain Drug Stores (...inistration (FDA). The letter expresses the Assoc... both domestic and foreign, that are engaged in a ...ing and dispensing of prescription medications. ,...
(Date:11/25/2009)...HINGTON,Nov.25/PRNewswire-USNewswire/--/EINNews/EI...sssyndication,introducesitsnewesthealth-relatedpub...wsToday( http://h1n1.einnews.com ). ,, H1N1News...micfromgovernments,newsoutletsandresearchcentersth...latestnewsontheglobaloutbreakwithreportsfromeverys...
Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance-California Releases 2nd Annual State-Specific Report Card On Lung Cancer 2Health News:1 of LA BioMed's founders to be honored 2Health News:Natural Soy Component May Help Treat Colon Cancer 2Health News:NACDS Supports FDA Enforcement Against Rogue Internet Pharmacy Websites 2Health News:H1N1 News Today Examines the Swine Flu Virus From a Global Perspective; Read the Latest H1N1 Virus Vaccine & Prevention News From EIN News 2
...aths due to heart disease is on the rise. Statisti...art problems//. Hence The National Council for...he health officials to treat patients suffering fr... The National Health Service (NHS) has asked th...
... fertility kit, which is termed as the Plan Ahead ...lemma and helps them to decide about their pregnan... launched in the market after completing all the n...e results help the women to decide on the time int...
...udy conducted by David Flora, PhD of the Universit...ersity), and Laurie Chassin, PhD of Arizona State ...ectly linked to illicit drug well into adulthood. ...on has been established between alcohol abuse in p...
...er male foetus can easily be destroyed by the stre...d other natural calamities including severe famine...nger life than average, according to a study condu... stress have less tolerance for unhealthy embryos ...
...known fact that your race has a profound effect on...search held at University of Massachusetts// and P...redictor of plasma lipids in patients with HIV-1 o...up studies. The main thrust was to look at the way...
...ganisms present in the soil can be used to clean t... according to the scientists belonging to the Univ...York’s Professor Neil Bruce is reported to have Is... However, on finding that the bacteria present i...
Other Medicine News:Health News:New fertility kit, analyzes the woman's ability to conceive 2
...with the safety and comfort of the practitioner in...F-6) leaded glass, the industry standard for radia... as set for optical clarity, visible light transmi...ewear is protecting your eyes, it also helps you l...
...with the safety and comfort of the practitioner in...F-6) leaded glass, the industry standard for radia... as set for optical clarity, visible light transmi...ewear is protecting your eyes, it also helps you l...
Radiation Protection Goggles
Ultralight Jarrod Goggles
Medicine Products: